RxDoctor Payments Data

Anthony Cossell, MD

Interventional Cardiology · Noblesville, INNPI 1639178452

Payments from drug & device makers

$3,749in general payments, 2019–2025

Across 122 payments — averaging $30.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$828
  • Boston Scientific$638
  • Abbott$319
  • AstraZeneca$293
  • Boehringer Ingelheim$184
  • Pfizer$172
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$1253%
  • Food & beverage$3,50593%
  • Education$1203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,749 in reported general payments places this provider in the 30th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$34,192
Medicare patients
163
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$264,385
EntrestoSacubitril/Valsartan68$74,650
JardianceEmpagliflozin42$55,575
XareltoRivaroxaban25$33,233
Repatha SureclickEvolocumab21$25,396
FarxigaDapagliflozin Propanediol23$24,147
VascepaIcosapent Ethyl24$17,557
Ezetimibe220$3,670
Rosuvastatin Calcium299$3,483
Ranolazine ErRanolazine24$2,717
Metoprolol Succinate222$2,487
Eplerenone23$2,361
Atorvastatin Calcium221$2,256
ClopidogrelClopidogrel Bisulfate107$1,209
Olmesartan Medoxomil64$961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$264,385206 claims
NovartisEntresto$140$74,65068 claims
Boehringer IngelheimJardiance$184$55,57542 claims
Johnson & JohnsonXarelto$158$33,23325 claims
AstraZenecaFarxiga$293$24,14723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →